Stock Analysis on Net

Boston Scientific Corp. (NYSE:BSX)

$22.49

This company has been moved to the archive! The financial data has not been updated since May 4, 2023.

DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Two-Component Disaggregation of ROE

Boston Scientific Corp., decomposition of ROE

Microsoft Excel
ROE = ROA × Financial Leverage
Dec 31, 2022 = ×
Dec 31, 2021 = ×
Dec 31, 2020 = ×
Dec 31, 2019 = ×
Dec 31, 2018 = ×

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


Return on Assets (ROA)
The ROA exhibited significant volatility over the observed period. Starting at 7.96% in 2018, it increased markedly to 15.38% in 2019, indicating improved efficiency in asset utilization for generating profits. However, in 2020, ROA dropped dramatically to a negative value of -0.27%, suggesting a period of operational challenges or losses. Subsequently, the ROA recovered to positive figures, reaching 3.23% in 2021 and then slightly decreasing to 2.15% in 2022. This trend indicates partial recovery but remaining below the highs observed in 2019.
Financial Leverage
Financial leverage displayed a consistent downward trend from 2018 to 2022. The ratio decreased from 2.41 in 2018 to 1.85 in 2022. This steady decline suggests a gradual reduction in the reliance on debt financing relative to equity, potentially reflecting a strategic move towards lower financial risk or improved equity base over the period.
Return on Equity (ROE)
ROE followed a pattern similar to ROA, with pronounced fluctuations. It increased from 19.15% in 2018 to a peak of 33.87% in 2019, signifying strong profitability relative to shareholders' equity. The subsequent sharp decline to -0.54% in 2020 highlights a period of negative profitability for equity holders. Recovery was observed in the following years, with ROE climbing to 6.26% in 2021 and then settling at 3.97% in 2022, indicating some improvement but still significantly below the peak levels.

Three-Component Disaggregation of ROE

Boston Scientific Corp., decomposition of ROE

Microsoft Excel
ROE = Net Profit Margin × Asset Turnover × Financial Leverage
Dec 31, 2022 = × ×
Dec 31, 2021 = × ×
Dec 31, 2020 = × ×
Dec 31, 2019 = × ×
Dec 31, 2018 = × ×

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


Net Profit Margin
The net profit margin demonstrated significant volatility over the observed period. Initially, there was a strong increase from 17.01% in 2018 to a peak of 43.78% in 2019. However, this was followed by a steep decline to -0.83% in 2020, indicating a loss during that year. The margin showed some recovery subsequently, rising to 8.76% in 2021, but then decreased slightly to 5.5% in 2022. This pattern reflects fluctuating profitability with a notable downturn in 2020 and only partial recovery thereafter.
Asset Turnover
The asset turnover ratio steadily declined from 0.47 in 2018 to 0.32 in 2020, suggesting a decreasing efficiency in utilizing assets to generate sales. This trend reversed slightly in the subsequent years, increasing to 0.37 in 2021 and 0.39 in 2022, indicating a modest improvement in asset utilization but still below the initial 2018 level.
Financial Leverage
Financial leverage consistently decreased throughout the period, from 2.41 in 2018 down to 1.85 in 2022. This steady decline points to a reduction in the use of debt relative to equity, implying a more conservative capital structure and potentially lower financial risk over time.
Return on Equity (ROE)
The return on equity followed a pattern similar to the net profit margin. It increased markedly from 19.15% in 2018 to 33.87% in 2019, before dropping sharply to -0.54% in 2020, indicating a loss year. Partial recovery occurred in the following years, with ROE rising to 6.26% in 2021 but declining slightly to 3.97% in 2022. This reflects overall volatility in profitability and returns to shareholders during the period.

Five-Component Disaggregation of ROE

Boston Scientific Corp., decomposition of ROE

Microsoft Excel
ROE = Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Financial Leverage
Dec 31, 2022 = × × × ×
Dec 31, 2021 = × × × ×
Dec 31, 2020 = × × × ×
Dec 31, 2019 = × × × ×
Dec 31, 2018 = × × × ×

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


The analysis of the financial ratios over the five-year period reveals several notable trends and fluctuations in the company’s profitability, efficiency, and financial structure.

Tax Burden
This ratio exhibited significant volatility, with a sharp increase from 1.18 in 2018 to 6.84 in 2019, suggesting an unusual tax situation or adjustment during that year. However, data for 2020 is missing. The ratio then declined markedly to below 1.0 in the subsequent years, reaching 0.61 by 2022, indicating a reduction in effective tax burden on the company’s earnings in recent years.
Interest Burden
The interest burden ratio demonstrated a downward trend from 0.86 in 2018 to a negative value of -0.28 in 2020, indicating an abnormal situation, probably related to net interest income surpassing interest expense or an accounting anomaly. It then recovered to positive values around 0.7 in 2021 and 2022, though remaining lower than the 2018 level, suggesting less impact of interest costs on earnings in the later periods.
EBIT Margin
The EBIT margin showed a declining trend from 16.93% in 2018 to a low of 2.84% in 2020, reflecting significant erosion of operating profitability that year. Subsequently, profitability improved steadily to 11.92% in 2021 and 12.7% in 2022, although it did not return to the levels observed in 2018, indicating some recovery but ongoing pressure on operating efficiency or costs.
Asset Turnover
This ratio decreased gradually from 0.47 in 2018 to 0.32 in 2020, indicating reduced efficiency in generating sales from assets. A modest recovery was observed in 2021 and 2022, reaching 0.39, but it remained below earlier levels, pointing to persistent challenges in asset utilization.
Financial Leverage
Financial leverage steadily declined from 2.41 in 2018 to 1.85 in 2022, suggesting a progressive reduction in debt relative to equity. This trend indicates a deleveraging strategy, which could reduce financial risk but might also constrain growth or return opportunities.
Return on Equity (ROE)
The ROE showed substantial variability, peaking at 33.87% in 2019 after a moderate 19.15% in 2018, likely benefiting from leverage and profitability factors in that period. However, it fell sharply to -0.54% in 2020, reflecting a loss or very poor profitability. Although indicators improved in the following years, ROE remained low at 6.26% in 2021 and further declined to 3.97% in 2022, highlighting challenges in generating returns for shareholders despite reduced leverage and some improvement in operating profits.

Overall, the period studied was marked by significant operational and financial stress around 2020, with some recovery in subsequent years. Improvements in EBIT margin and asset turnover after 2020 indicate progress in operational performance, but the persistent low ROE and reduced financial leverage suggest cautious management and ongoing challenges in achieving strong profitability and return on equity.


Two-Component Disaggregation of ROA

Boston Scientific Corp., decomposition of ROA

Microsoft Excel
ROA = Net Profit Margin × Asset Turnover
Dec 31, 2022 = ×
Dec 31, 2021 = ×
Dec 31, 2020 = ×
Dec 31, 2019 = ×
Dec 31, 2018 = ×

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


Net Profit Margin
The net profit margin exhibited significant variability over the five-year period. Starting at 17.01% in 2018, it peaked notably at 43.78% in 2019. However, the margin sharply declined to a negative value of -0.83% in 2020, indicating a loss during that year. Subsequently, the margin recovered to positive territory with 8.76% in 2021, but decreased again to 5.5% in 2022. Overall, the trend reflects considerable volatility with a marked recovery after 2020 losses, yet remaining below the peak value observed in 2019.
Asset Turnover
The asset turnover ratio demonstrated a general downward trend from 0.47 in 2018 to 0.32 in 2020, suggesting reduced efficiency in using assets to generate revenue during that period. After 2020, the ratio increased slightly to 0.37 in 2021 and further to 0.39 in 2022. Although there was some recovery, the values remained lower than the initial 2018 figure, indicating a partial improvement but also a maintained decline in asset utilization efficiency relative to the start of the period.
Return on Assets (ROA)
The return on assets followed a pattern similar to the net profit margin. It began at 7.96% in 2018 and nearly doubled to 15.38% in 2019, reflecting strong asset profitability. In 2020, ROA fell into negative territory at -0.27%, corresponding with the net profit margin’s loss that year. While the metric rebounded to 3.23% in 2021 and then decreased slightly to 2.15% in 2022, the overall trend after 2019 indicates a material decline in asset profitability with only partial recovery through 2022.

Four-Component Disaggregation of ROA

Boston Scientific Corp., decomposition of ROA

Microsoft Excel
ROA = Tax Burden × Interest Burden × EBIT Margin × Asset Turnover
Dec 31, 2022 = × × ×
Dec 31, 2021 = × × ×
Dec 31, 2020 = × × ×
Dec 31, 2019 = × × ×
Dec 31, 2018 = × × ×

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


Tax Burden
The tax burden ratio exhibited significant fluctuations over the period. It peaked sharply in 2019 at 6.84, indicating an unusually high tax impact that year, before returning to values below 1 in subsequent years, settling at 0.61 in 2022. This suggests a substantial variability in tax expense relative to pre-tax income, with 2019 standing out as an outlier.
Interest Burden
The interest burden ratio showed a declining trend from 0.86 in 2018 to 0.59 in 2019, dropped to a negative value of -0.28 in 2020, then improved again in 2021 and 2022 to 0.76 and 0.71 respectively. The negative value in 2020 indicates an extraordinary event, possibly interest income exceeding interest expense or a misclassification that year, followed by a partial recovery in subsequent years.
EBIT Margin
The EBIT margin experienced a sharp decline from 16.93% in 2018 to 2.84% in 2020, illustrating a significant reduction in operational profitability during that period. However, the margin rebounded in 2021 and 2022 to 11.92% and 12.7% respectively, indicating a recovery in operational efficiency and profitability.
Asset Turnover
The asset turnover ratio steadily declined from 0.47 in 2018 to 0.32 in 2020, suggesting decreasing efficiency in utilizing assets to generate sales. This ratio then showed a mild improvement in 2021 and 2022, increasing to 0.37 and 0.39, indicating some recovery in asset utilization.
Return on Assets (ROA)
The ROA displayed notable volatility, with an initial increase from 7.96% in 2018 to a peak of 15.38% in 2019, followed by a sharp decline to negative -0.27% in 2020. Post-2020, ROA recovered partially but remained relatively low at 3.23% in 2021 and 2.15% in 2022. These movements reflect significant fluctuations in overall profitability relative to asset base during the period.

Disaggregation of Net Profit Margin

Boston Scientific Corp., decomposition of net profit margin ratio

Microsoft Excel
Net Profit Margin = Tax Burden × Interest Burden × EBIT Margin
Dec 31, 2022 = × ×
Dec 31, 2021 = × ×
Dec 31, 2020 = × ×
Dec 31, 2019 = × ×
Dec 31, 2018 = × ×

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


Tax Burden
The Tax Burden ratio shows significant fluctuation over the observed periods. It was 1.18 in 2018 but rose sharply to 6.84 in 2019, suggesting a notable change in tax effects or profitability structure. The data for 2020 is missing. In 2021 and 2022, the ratio decreased markedly to 0.97 and further to 0.61, indicating a normalization or reduction in tax-related expenses relative to income.
Interest Burden
The Interest Burden ratio declined from 0.86 in 2018 to 0.59 in 2019, reflecting increased interest expenses or reduced earnings before interest and taxes. In 2020, the ratio became negative at -0.28, which could indicate extraordinary financial circumstances or accounting adjustments affecting EBIT negatively relative to earnings before tax. The ratio recovered in 2021 to 0.76 and slightly decreased in 2022 to 0.71, suggesting stabilization in interest costs and operational earnings.
EBIT Margin
The EBIT Margin experienced a broad decline from 16.93% in 2018 to a low of 2.84% in 2020, pointing to deteriorating operational profitability likely influenced by external market or internal business factors. Recovery is observed in subsequent years, with margins increasing to 11.92% in 2021 and 12.7% in 2022, indicating improved operational efficiency or revenue growth contributing to better earnings before interest and taxes.
Net Profit Margin
The Net Profit Margin displayed extreme volatility, starting at 17.01% in 2018 and peaking dramatically at 43.78% in 2019. This spike may reflect exceptional gains or accounting effects. In 2020, profitability turned negative at -0.83%, signifying a net loss during that period. A partial recovery ensued, with net margin rising to 8.76% in 2021 and then declining slightly to 5.5% in 2022, reflecting ongoing challenges in maintaining stable profitability after the loss.